5. Suggested reading

WHO policy guidance on TB diagnostics and laboratory strengthening

Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children. Policy update (WHO/HTM/TB/2013.16). Geneva: World Health Organization; 2013 (https://apps.who.int/iris/bitstream/handle/10665/112472/9789241506335_eng.pdf;jsessi onid=C6DD5DFBE6B8B0264DE8E02946EBF290?sequence=1).

WHO End TB Strategy: global strategy and targets for tuberculosis prevention, care and control after 2015. Geneva: World Health Organization; 2015 (https://www.who.int/publications/i/item/WHO-HTM-TB-2015.19).

Implementing tuberculosis diagnostics: a policy framework (WHO/HTM/TB/2015.11). Geneva: World Health Organization; 2015 (https://www.who.int/publications/i/item/9789241508612).

Chest radiography in tuberculosis detection: summary of current WHO recommendations and guidance on programmatic approaches. Geneva: World Health Organization; 2016 (https:// www.who.int/publications/i/item/9789241511506).

Framework of indicators and targets for laboratory strengthening under the End TB Strategy (WHO/HTM/TB/2016.18). Geneva: World Health Organization; 2016 (https://www.who.int/publications/i/item/9789241511438).

Frequently asked questions about the implementation of the new WHO recommendation on the use of the shorter MDR-TB regimen under programmatic conditions (Version: 20 December 2016). Geneva: World Health Organization; 2016 (https://www.who.int/tb/areas-of-work/drug-resistant-tb/treatment/FAQshorter_MDR_regimen.pdf?ua=1).

The use of molecular line probe assays for the detection of resistance to isoniazid and rifampicin. Policy update (WHO/HTM/TB/2016.12). Geneva: World Health Organization; 2016 (https://www.who.int/publications/i/item/9789241511261).

The use of molecular line probe assays for the detection of resistance to second-line anti-tuberculosis drugs. Policy guidance (WHO/HTM/TB/2016.07). Geneva: World Health Organization; 2016 (https://www.who.int/publications/i/item/9789241510561).

Considerations for adoption and use of multi-disease testing devices in integrated laboratory networks (WHO/HTM/TB/2017.06). Geneva: World Health Organization; 2017 (https://www.who.int/publications/i/item/WHO-HTM-TB-2017.06).

Planning for country transition to Xpert MTB/RIF Ultra cartridges. Geneva: Global Laboratory Initiative; 2017 (http://stoptb.org/wg/gli/assets/documents/GLI_ultra.pdf).

WHO meeting report of a technical expert consultation: non-inferiority analysis of Xpert MTB/RIF Ultra compared to Xpert MTB/RIF (WHO/HTM/TB/2017.04). Geneva: World Health Organization; 2017 (https://www.who.int/publications/i/item/WHO-HTM-TB-2017.04).

Line probe assays for drug-resistant tuberculosis detection: interpretation and reporting guide for laboratory staff and clinicians. Geneva: Global Laboratory Initiative; 2018 (http://www.stoptb.org/wg/gli/assets/documents/LPA_test_web_ready.pdf).

Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis (WHO/CDS/TB/2018.24). Geneva: World Health Organization; 2018 (https://www.who.int/publications/i/item/9789241514842).

WHO treatment guidelines for isoniazid-resistant tuberculosis: supplement to the WHO treatment guidelines for drug-resistant tuberculosis (WHO/CDS/TB/2018.7). Geneva: World Health Organization; 2018 (https://apps.who.int/iris/bitstream/handle/10665/260494/9789241550079-eng.pdf).

Rapid communication: key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB) (WHO/CDS/TB/2019.26). Geneva: World Health Organization; 2018 (https://www.who.int/tb/publications/2019/WHO_RapidCommunicationMDRTB2019.pdf?ua=1).

Lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis of active tuberculosis in people living with HIV. Policy update. Geneva: World Health Organization; 2019 (https://www.who.int/publications/i/item/9789241550604).

WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2020. (https://www.who.int/publications/i/item/9789240007048)

Frequently asked questions on the WHO rapid communication 2019: key changes to the treatment of drug-resistant TB. Geneva: World Health Organization; 2020 (https://www.who. int/tb/areas-of-work/drug-resistant-tb/faqs-updated-final-version.pdf?ua=1).

Guidance on implementation of diagnostic testing

GLI model TB diagnostic algorithms. Geneva: Global Laboratory Initiative; 2017 (http://www.stoptb.org/wg/gli/assets/documents/GLI_algorithms.pdf).

GLI practical guide to TB laboratory strengthening. Geneva: Global Laboratory Initiative; 2017 (http://stoptb.org/wg/gli/gat.asp).

GLI specimen referral toolkit. Geneva: Global Laboratory Initiative; 2017 (http://www.stoptb. org/wg/gli/srt.asp).

Training packages

Training package on culture in solid and liquid media. Geneva: Global Laboratory Initiative; 2012 (http://www.stoptb.org/wg/gli/documents.asp?xpand=2).

Training package on DST by phenotypic and molecular method. Geneva: Global Laboratory Initiative; 2012 (http://www.stoptb.org/wg/gli/documents.asp?xpand=2).

Training package on line probe assays (LPAs). Geneva: Global Laboratory Initiative; 2012 (http://www.stoptb.org/wg/gli/documents.asp?xpand=2).

Training package on Xpert MTB/RIF. Geneva: Global Laboratory Initiative; 2014 (http://www.stoptb.org/wg/gli/documents.asp?xpand=2).

Training package: programme modules for diagnostic network strengthening. Geneva: Global Laboratory Initiative; 2018 (http://stoptb.org/wg/gli/TrainingPackage_Programme.asp).

Book navigation